• Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints,
and its secondary endpoint of complete wound healing at three-month timepoints
VYJUVEKTM was well tolerated, with no drug-related serious adverse events or discontinuations
Biologics License Application (BLA) on track to be submitted to U.S. Food and Drug Administration (FDA) in 1H22
Conference call to discuss results scheduled for today, Monday, November 29, 2021 at 8:00 a.m. EST
Investor Conference Call, Webcast and Presentation Information
Krystal will host an investor conference call and webcast today, Monday, November 29, at 8:00 a.m. ET, to discuss topline results from the pivotal GEM-3 trial and the VYJUVEKTM program. To participate in the conference call, please dial 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and refer to conference ID 13725260. The webcast, which will include presentation slides, will be available live and for replay on Krystal’s website at www.krystalbio.com in the Investors section.
https://finance.yahoo.com/news/krystal-biotech-announces-positive-topline-120000999.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.